Tackling the toughest challenges in medicine with the aspiration to cure human diseases.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $156M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | LAV | lavfund.co... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Alpha Wave... | alphawaveg... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.09.2018 | Series C | $80M | - |
| 02.10.2017 | - | $76M | - |
Mentions in press and media 11
| Date | Title | Description |
| 28.09.2018 | Term Sheet — Friday, September 28 | THREE THINGS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop DIRTY DEALINGS: I first reported on ‘Uber for trash’ startup Rubicon Global almost exactly one year ago when I reviewed mul... |
| 28.09.2018 | KSQ Therapeutics Secures $80 Million | KSQ Therapeutics announced today that the company has secured an $80 million Series C financing to advance oncology drug candidates generated from the company’s proprietary CRISPRomics drug discovery engine into clinical studies. With the f... |
| 28.09.2018 | KSQ Therapeutics Secures $80M Financing Round | KSQ Therapeutics, a Cambridge, MA-based developer of oncology drugs, secured an $80m Series C financing. Backers included Baillie Gifford, Cowen Healthcare Investments, Invus, Lilly Asia Ventures, Flagship Pioneering, Polaris Partners, ARCH... |
| 28.09.2018 | KSQ Therapeutics closes $80M Series C for cell therapy developed with CRISPR-based platform | The company plans to use the funding to advance its first program into the clinic within the next year and a half, a tumor-infiltrating lymphocyte, or TIL therapy – a type of adoptive T-cell therapy – that it has thus far tested in animal m... |
| 28.09.2018 | KSQ Therapeutics Secures $80M Financing | CAMBRIDGE, MA, KSQ Therapeutics announced today that the company has secured an $80 million Series C financing. >> Click here for more funding data on KSQ Therapeutics >> To export KSQ Therapeutics funding data to PDF and Ex... |
| 03.10.2017 | Term Sheet — Tuesday, October 3 | DIRTY DEALINGS Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop But as I noted before, the numbers didn’t add up. Yesterday, Bloomberg published a story about how the company has overstated it... |
| 02.10.2017 | KSQ Therapeutics Launches with $76M in Financing | KSQ Therapeutics, a Cambridge, MA-based drug development company, has just come out of stealth with a $76m equity financing. The round was led by Flagship Pioneering with participation from Polaris Partners, ARCH Venture Partners, and Alexa... |
| 02.10.2017 | KSQ Therapeutics Emerges with $76M Financing | CAMBRIDGE, MA, KSQ Therapeutics emerged today with $76 million in financing. >> Click here for more funding data on KSQ Therapeutics >> To export KSQ Therapeutics funding data to PDF and Excel, click here KSQ Therapeutics... |
| 02.10.2017 | KSQ Therapeutics Raises $76 Million | CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics emerged today with $76 million in financing and a world-class executive team to advance the development of drugs empowered by the unique biological insights of its proprietary CRISPRomics ... |
| 02.10.2017 | KSQ raises $76M, names ex-Genzyme boss Meeker as CEO | KSQ Therapeutics has raised $76 million and named former Genzyme boss David Meeker as CEO. Meeker is taking charge of a biotech that spent the past 18 months interrogating 20,000 human genes across 600 cancer- and immune-based models, provi... |
Show more